Sofwave Medical

The Regenerative Aesthetics Company

Health Tech & Life Sciences
Public on TASE on May, 2021<br>

Company Overview

Snapshot

Founded in October 2015 by Shimon Eckhouse, Ariel Sverdlik, and Genady Nahshon, Sofwave Medical operates with 51–200 employees. The company has raised $58.4M across two funding rounds. In May 2021, Sofwave Medical went public on the TASE, raising $50M.

Business overview

Sofwave Medical specializes in non-invasive aesthetic medical solutions designed to improve skin laxity, provide lifting effects, and enhance muscle toning. The company utilizes its proprietary Synchronous Ultrasound Parallel Beam Technology (SUPERB™) to deliver controlled ultrasound energy to the mid-dermal layer, stimulating collagen and elastin production for improved skin appearance with minimal downtime. Sofwave's product portfolio includes the Pure Impact add-on module, the world’s first plyometric muscle activation and toning device, which offers increased treatment versatility and efficiency. These technologies are clinically validated and supported by multiple broad FDA clearances, serving patients and healthcare providers in the aesthetic and medical device sectors.

Strategic signal

In September 2025, Sofwave Medical received FDA pre-market clearance for its Pure Impact VIPTM Standalone EMS Device, designed for comprehensive multi-body area muscle strengthening and firming. This clearance signals a significant expansion of Sofwave's product offerings beyond its core ultrasound technology, entering the muscle activation and toning market. For investors, this indicates a strategic move to diversify revenue streams and address a broader range of aesthetic concerns, potentially increasing market penetration and competitive advantage.

Company Intelligence Q&A

What was a significant regulatory achievement for Sofwave Medical in September 2025?
In September 2025, Sofwave Medical received FDA pre-market clearance for its Pure Impact VIPTM Standalone EMS Device, which is designed for comprehensive multi-body area muscle strengthening and firming.
When did Sofwave Medical go public and how much capital was raised?
Sofwave Medical went public on the TASE in May 2021, raising $50M.
What patent did Sofwave Medical obtain in October 2024?
In October 2024, Sofwave Medical obtained a U.S. Patent for Fat Tissue Reduction Technology.
What award did Sofwave Medical receive in November 2023?
In November 2023, Sofwave Medical earned Frost & Sullivan's 2023 North American Technology Innovation Leadership Award for developing a sophisticated skin tightening ultrasound technology with minimal downtime.
What was a key regulatory milestone for Sofwave Medical in November 2022?
In November 2022, Sofwave Medical gained approval to market the SUPERB™ Non-Invasive Wrinkle Reduction Device in Brazil.

External links